Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Xencor IncfiledCriticalGenentech Inc
Publication of AR120193A1publicationCriticalpatent/AR120193A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
La presente se refiere a proteínas de fusión que comprenden proteínas IL-15 variantes, proteínas de fusión que comprenden anticuerpos anti-PD-1 variantes y proteínas de fusión que comprenden proteínas IL-15 variantes y anticuerpos anti-PD-1 variantes. La presente también se refiere a moléculas de ácido nucleico, vectores de expresión, células huésped y métodos para elaborar tales proteínas de fusión y el uso de tales proteínas de fusión en el tratamiento del cáncer.The present relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antibodies, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antibodies. The present invention also relates to nucleic acid molecules, expression vectors, host cells, and methods of making such fusion proteins and the use of such fusion proteins in the treatment of cancer.
ARP200102805A2019-10-112020-10-09
IL-15/IL-15Ra FC FUSION PROTEINS ACTING ON PD-1 WITH ENHANCED PROPERTIES
AR120193A1
(en)
bispecific heterodimeric protein, nucleic acid and expression vector compositions, expression vector, host cell, and methods for producing bispecific heterodimeric protein and for treating cancer in a patient